Published in Chest on September 01, 2005
Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging (2008) 1.91
Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging (2016) 1.54
Patterns of late gadolinium enhancement in chronic hemodialysis patients. JACC Cardiovasc Imaging (2008) 1.48
Sarcoid heart disease. Postgrad Med J (2007) 1.13
Cardiovascular magnetic resonance in the evaluation of heart failure. Heart (2007) 1.00
Advances in clinical applications of cardiovascular magnetic resonance imaging. Heart (2008) 0.96
The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy. Heart Fail Rev (2011) 0.90
Distribution of late gadolinium enhancement in various types of cardiomyopathies: Significance in differential diagnosis, clinical features and prognosis. World J Cardiol (2014) 0.85
Management of cardiac sarcoidosis in the United States: a Delphi study. Chest (2011) 0.83
Applications of cardiac magnetic resonance in electrophysiology. Circ Arrhythm Electrophysiol (2009) 0.82
Capability of three-dimensional speckle tracking radial strain for identification of patients with cardiac sarcoidosis. Int J Cardiovasc Imaging (2012) 0.78
Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes. World J Cardiol (2012) 0.78
Cardiomyopathy of uncertain etiology: Complementary role of multimodality imaging with cardiac MRI and 18FDG PET. J Nucl Cardiol (2010) 0.77
Reduced oxygen uptake efficiency slope in patients with cardiac sarcoidosis. PLoS One (2014) 0.77
Intra-cardiac distribution of late gadolinium enhancement in cardiac sarcoidosis and dilated cardiomyopathy. World J Cardiol (2016) 0.75
Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis. JACC Cardiovasc Imaging (2016) 0.75
Magnetic resonance imaging of cardiac sarcoidosis: an evaluation of the cardiac segments and layers that exhibit late gadolinium enhancement. Nagoya J Med Sci (2016) 0.75
Notice from the editor-in-chief and the ethics subcommittee of CHEST associate editors. Chest (2007) 0.75
Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging (2006) 0.75
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol (2005) 2.93
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
Diagnostic accuracy and clinical utility of noninvasive testing for coronary artery disease. Ann Intern Med (2010) 2.80
Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation (2006) 2.63
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) 2.50
Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomised trial. Br J Gen Pract (2010) 2.42
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 2.30
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol (2011) 2.19
Who is at risk of post-MI depressive symptoms? J Psychosom Res (2005) 2.18
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet (2012) 2.14
Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. Eur Radiol (2012) 2.14
Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation (2013) 2.11
Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol (2004) 2.10
Effect of smoke-free legislation on the incidence of sudden circulatory arrest in the Netherlands. Heart (2012) 2.10
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09
Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation). J Am Coll Cardiol (2013) 2.08
Performance of angiographic, electrocardiographic and MRI methods to assess the area at risk in acute myocardial infarction. Heart (2011) 2.06
Combined anterior and inferior ST-segment elevation Electrocardiographic differentiation between right coronary artery occlusion with predominant right ventricular infarction and distal left anterior descending branch occlusion. J Electrocardiol (2011) 2.04
Efficient quantification of the left ventricular volume using 3-dimensional echocardiography: the minimal number of equiangular long-axis images for accurate quantification of the left ventricular volume. J Am Soc Echocardiogr (2007) 1.93
Relation of levels of serum lipoproteins to depression after acute myocardial infarction. Am J Cardiol (2002) 1.92
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol (2009) 1.87
Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study--TROFI trial. Eur Heart J (2013) 1.87
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis (2011) 1.84
Depression following myocardial infarction: first-ever versus ongoing and recurrent episodes. Gen Hosp Psychiatry (2005) 1.76
Acute results of transvenous cryoablation of supraventricular tachycardia (atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, atrioventricular nodal reentry tachycardia). J Cardiovasc Electrophysiol (2002) 1.72
Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol (2005) 1.71
Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J (2005) 1.71
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68
How important is the electrocardiogram in protecting and guiding the athlete? Circulation (2011) 1.68
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys (2009) 1.67
Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J (2008) 1.64
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J (2003) 1.63
Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J Mol Cell Cardiol (2007) 1.61
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace (2011) 1.61
Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J (2011) 1.60
The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace (2010) 1.59
Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57
Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate. J Cardiovasc Electrophysiol (2004) 1.57
Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Changes in mitral regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2010) 1.54
Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J (2004) 1.54
Calculation of effective VV interval facilitates optimization of AV delay and VV interval in cardiac resynchronization therapy. Heart Rhythm (2006) 1.54
The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol (2011) 1.51
Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J (2008) 1.51
Magnetic navigation system used successfully to cross a crushed stent in a bifurcation that failed with conventional wires. Catheter Cardiovasc Interv (2007) 1.50
Short- and long-term major adverse cardiac events in patients undergoing percutaneous coronary intervention with stenting for acute myocardial infarction complicated by cardiogenic shock. Cardiology (2012) 1.46
Validity of coronary heart diseases and heart failure based on hospital discharge and mortality data in the Netherlands using the cardiovascular registry Maastricht cohort study. Eur J Epidemiol (2009) 1.45
Clinical outcome following Transcatheter Aortic Valve Implantation in patients with impaired left ventricular systolic function. Catheter Cardiovasc Interv (2012) 1.45
How to enhance acute outcome of electrical cardioversion by drug therapy: importance of immediate reinitiation of atrial fibrillation. J Cardiovasc Electrophysiol (2002) 1.45
Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace (2011) 1.45
Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years. Catheter Cardiovasc Interv (2012) 1.45
NIRS and IVUS for characterization of atherosclerosis in patients undergoing coronary angiography. JACC Cardiovasc Imaging (2011) 1.42
RR-interval irregularity precedes ventricular fibrillation in ST elevation acute myocardial infarction. Heart Rhythm (2009) 1.42
Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J (2007) 1.42
Validity and variability in visual assessment of stenosis severity in phantom bifurcation lesions: a survey in experts during the fifth meeting of the European Bifurcation Club. Catheter Cardiovasc Interv (2011) 1.42
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace (2013) 1.42
Will future troponin measurement overrule the ECG as the primary diagnostic tool in patients with acute coronary syndrome? J Electrocardiol (2013) 1.42
Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? Heart Rhythm (2005) 1.42
Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol (2007) 1.42
Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention (2015) 1.40
Atrial natriuretic peptides during experimental atrial tachycardia: role of developing tachycardiomyopathy. J Cardiovasc Electrophysiol (2004) 1.40
Evaluation of the electrocardiogram in identifying and quantifying lateral involvement in nonanterior wall infarction using cardiovascular magnetic resonance imaging. J Electrocardiol (2012) 1.39
MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res (2004) 1.39
Pulmonary vein isolation using transvenous catheter cryoablation for treatment of atrial fibrillation without risk of pulmonary vein stenosis. J Am Coll Cardiol (2003) 1.36
Left bundle branch block induces ventricular remodelling and functional septal hypoperfusion. Eur Heart J (2004) 1.36